Amprion Receives Financing From Decathlon Capital Partners

The company will use the funding to expand its diagnostic testing capacity for diseases including Parkinson's disease, Lewy body dementia, and Alzheimer's disease.

"Demand for Amprion's testing is increasing worldwide as researchers and clinicians recognize the value of reliable, pathology-based insights into Parkinson's disease, Lewy body dementia and related neurodegenerative disorders," said Russ Lebovitz, CEO of Amprion. "This investment from Decathlon Capital Partners strengthens our ability to meet that demand and accelerate the global adoption of our seed-amplification testing.

Read More:QIZ Security Raises $17M in Seed Funding Led by Merlin Ventures

"Amprion is addressing a critical need in neurological care through its commitment to earlier and more accurate diagnosis of neurodegenerative diseases," said Matt Hoffman, Managing Director of Decathlon Capital Partners. "We are proud to partner with the company as it scales its innovative testing platform, and expands access for physicians and researchers worldwide."

About Amprion

Founded in 2007 by Russell Lebovitz and Claudio Soto, Amprion develops diagnostic tests for neurodegenerative diseases using seed amplification technology. The company also supports research, drug development and commercialization through its expertise and intellectual property in seed amplification assays.

Read More:Ollama Raises $65M in Series B Funding Led by Theory Ventures